twenty-six patients with non-lymphocytic acute leukemia , who had achieved a complete remission with induction chemotherapy consisting of daunorubicin ( 45 mg/m2/day , day 1 , 2 and 3 ) and cytosine-arabinoside ( 100 mg/m2/day , continuous infusion , day 1 to day 7 ) were entered into a randomized trial .
C0023467
non-lymphocytic acute leukemia
C0011015
daunorubicin